Lumos Diagnostics Holdings Ltd. (AU:LDX)
ASX:LDX
Want to see AU:LDX full AI Analyst Report?
LDX Stock Chart & Stats
AU$0.32
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.32
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.33
Previous CloseN/A
Volume213.94K
Average Volume (3M)5.63M
Market Cap
AU$103.88M
Enterprise ValueAU$67.83M
Total Cash (Recent Filing)AU$3.00M
Total Debt (Recent Filing)AU$11.85M
Price to Earnings (P/E)―
Beta2.02
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding944,389,160
10 Day Avg. Volume3,659,446
30 Day Avg. Volume5,628,467
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.96
Price to Sales (P/S)0.97
P/FCF Ratio-1.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$20.86M
Bulls Say, Bears Say
Bulls Say
Secure 6-year U.S. Distribution DealA guaranteed minimum USD 317M over six years provides durable revenue visibility and de-risks early commercial scaling. The deal gives Lumos predictable demand and partner-led distribution, supporting production planning, sales investment and long-term commercial footprint in the U.S. market.
Medicare Reimbursement SecuredSecured Medicare/MAC reimbursement at USD 41.38 per test materially improves unit economics for physician-office use. Payer coverage reduces adoption barriers, supports sustained physician demand, and makes hospital/pharmacy rollouts more commercially viable over the coming years.
High Gross Margins And Improving Cash FlowSustained gross margins (~68%) and product margins north of 60% indicate strong per-unit economics for FebriDx. Combined with a turn to positive operating cash flow in the last half and nondilutive funding, this supports reinvestment and a structurally stronger path to profitability if volumes scale as contracted.
Bears Say
Dependence On Pending CLIA WaiverThe CLIA waiver is a binary regulatory milestone that materially expands in-office addressable market and activates the PHASE distribution economics. Delay or denial would structurally postpone volume adoption, compress realized revenue vs. contracted expectations and increase commercialization risk over the medium term.
High Leverage And Weak Balance SheetA debt-to-equity ratio above 1.0 and negative ROE indicate constrained financial flexibility to fund scale-up. Persistent leverage raises refinancing and covenant risks, could force dilutive equity raises or costly debt, and limits ability to invest timely in manufacturing and go-to-market expansion.
Persistent Losses And Weak Cash GenerationNegative revenue growth (-14.8%), ongoing adjusted EBITDA losses and historically negative operating/free cash flow show structural profitability challenges. Even with recent improvements, sustained cash generation is not yet proven and the company may need additional financing to fund capacity and commercialization beyond initial contracted volumes.
Lumos Diagnostics Holdings Ltd. News
LDX FAQ
What was Lumos Diagnostics Holdings Ltd.’s price range in the past 12 months?
Lumos Diagnostics Holdings Ltd. lowest share price was AU$0.03 and its highest was AU$0.33 in the past 12 months.
What is Lumos Diagnostics Holdings Ltd.’s market cap?
Lumos Diagnostics Holdings Ltd.’s market cap is AU$103.88M.
When is Lumos Diagnostics Holdings Ltd.’s upcoming earnings report date?
Lumos Diagnostics Holdings Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 69 days.
How were Lumos Diagnostics Holdings Ltd.’s earnings last quarter?
Lumos Diagnostics Holdings Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.009.
Is Lumos Diagnostics Holdings Ltd. overvalued?
According to Wall Street analysts Lumos Diagnostics Holdings Ltd.’s price is currently Overvalued.
Does Lumos Diagnostics Holdings Ltd. pay dividends?
Lumos Diagnostics Holdings Ltd. does not currently pay dividends.
What is Lumos Diagnostics Holdings Ltd.’s EPS estimate?
Lumos Diagnostics Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lumos Diagnostics Holdings Ltd. have?
Lumos Diagnostics Holdings Ltd. has 944,389,160 shares outstanding.
What happened to Lumos Diagnostics Holdings Ltd.’s price movement after its last earnings report?
Lumos Diagnostics Holdings Ltd. reported an EPS of -AU$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.843%.
Which hedge fund is a major shareholder of Lumos Diagnostics Holdings Ltd.?
Currently, no hedge funds are holding shares in AU:LDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lumos Diagnostics Holdings Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:LDX Sentiment 90%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$150.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
551.51%
12-Months-Change
Fundamentals
Return on Equity
-164.12%
Trailing 12-Months
Asset Growth
-26.05%
Trailing 12-Months
Company Description
Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Limited is a contract research and development firm dedicated to designing and bringing to market fast, point-of-care (POC) diagnostic tests. The company primarily targets the detection and management of infectious diseases within the United States and Australia. Among its product offerings are FebriDx, a POC diagnostic test capable of differentiating between viral and bacterial respiratory infections; ViraDx, a combined POC test that identifies influenza A, influenza B, and COVID-19; and CoviDx, a rapid antigen test for COVID-19. Lumos also supplies complementary reader devices, including desktop, disposable, and its own Lumos Leelu readers. This Melbourne, Australia-based company was established in 2004.
Technical Analysis
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Genetic Signatures Ltd.
―
Inoviq Ltd
―
Microba Life Sciences Limited
―
Options Prices
Currently, No data available
---